Bayer to Close Mission Bay Innovation Center in Strategic R&D Consolidation

　　【Pharmaceutical Network Corporate News】Recently, in a statement, Bayer announced, "To fully leverage the company's resources and strive to harness internal and external innovation potential globally, Bayer has decided to consolidate its research and innovation activities in the Boston area of Massachusetts, USA. To this end, Bayer will close its Western North America Open Innovation Center located in Mission Bay."
 

It is reported that in May 2010, Bayer opened a branch in San Francisco, relocating 65 researchers to space vacated by Pfizer near the University of California, San Francisco (UCSF) Mission Bay campus. In 2012, the company opened the Mission Bay CoLaborator in the same building. This 6,000-square-foot incubation facility was primarily used to host R&D platforms, drug targets, or candidate drugs from relevant companies—ranging from startups to established enterprises—that potentially aligned with Bayer’s strategic development interests.
 

In fact, Bayer’s closure of its San Francisco R&D center to consolidate its innovative R&D activities is not an isolated case in the pharmaceutical industry. On November 18, 2019, Novartis Pharmaceuticals announced that it would close its early development R&D center in China, deciding to merge its Translational Clinical Oncology (TCO) team with the China Translational and Clinical Research team. Even earlier, GSK announced the closure of its neuroscience R&D center in Shanghai Zhangjiang. As one of GSK’s three major R&D centers, the Zhangjiang R&D center, established in 2007, was once a large-scale R&D facility for multinational corporations in China.
 

Based on this, industry analysts suggest that closing R&D centers is merely one strategy for multinational pharmaceutical companies to actively adjust their operations amid an increasingly competitive pharmaceutical landscape. In recent years, many multinational pharma companies have been accelerating the transformation of their business models by focusing on core market promotions, optimizing product portfolios, and implementing workforce reductions. Taking Eli Lilly as an example, an internal company email surfaced within the industry this March. The email revealed that Eli Lilly China has decided to restructure the sales and regional marketing teams for Jardiance, as well as the integrated sales teams for Cymbalta, Cialis, and Forteo (i.e., the CCO integrated team), to proactively respond to changes in the external environment and continuously advance the strategic transformation of its China business.
 

It is worth noting that, judging from the current development plans of numerous multinational pharmaceutical companies, the rapidly expanding Chinese pharmaceutical market is becoming a key strategic focus for industry leaders. According to reports, driven by the accelerated drug review and approval process in China, along with the continuous implementation of new policies encouraging innovation in drugs and medical devices and volume-based procurement, an increasing number of multinational pharmaceutical companies have begun disclosing their China market performance and are steadily accelerating adjustments to their local strategies. For instance, Novartis has experienced remarkably rapid market growth in China. Public data indicates that Novartis generated $2.6 billion in revenue in the Chinese market in 2020. That year, six new drugs and indications, including Patanol and Mayzent, gained approval in China, while eight new products and indications were successfully added to the National Reimbursement Drug List. According to prior guidance from Novartis management, its revenue in China is expected to sustain robust double-digit growth and is projected to double by 2024.
 

Industry experts believe that in the future, multinational pharmaceutical companies will not only continue to expand their presence in the Chinese market but will also proactively pursue strategic transformations to mitigate risks and make comprehensive preparations for future challenges. For Chinese pharmaceutical companies, this will provide valuable insights to understand and learn from the strategic initiatives of these multinationals in China, thereby better equipping them to navigate the intense market competition with global pharmaceutical firms in the years ahead.